Exosomes vs PRP: What the Evidence Says

As exosomes gain attention, the natural question from patients and practitioners alike is how they compare with PRP — platelet-rich plasma — the established regenerative option. They share a broad goal (delivering biological signals to prompt repair) but differ in ways that matter.

The Fundamental Difference: Origin

• PRP is autologous. It is made from the patient's own blood, drawn on the day, spun to concentrate the platelets and their growth factors, and used immediately. Nothing foreign is introduced.
• Exosomes are, in aesthetics, usually off-the-shelf and allogeneic (or non-human) — derived from cultured stem cells, other cells, or plant sources, and supplied as a manufactured product.

This single distinction drives most of the other differences.

Regulation

Because PRP is prepared from the patient's own blood within a single procedure, its regulatory position is well established. Exosome products, by contrast, are manufactured biologics, and injectable versions are not approved as regulated medicines in most jurisdictions — regulators have warned specifically about unapproved injectable exosome products. In practice this is why responsible exosome use stays topical and post-procedure, whereas PRP is routinely injected.

Evidence Base

PRP has a longer and larger body of published evidence across facial rejuvenation and, notably, hair restoration — it is an established protocol with known (if variable) results. Exosome evidence is younger and thinner: promising early reports, especially in combination with microneedling, but smaller studies and inconsistent products. On evidence maturity, PRP is currently ahead.

Convenience and Consistency

Here exosomes have a practical appeal: they are off-the-shelf, requiring no blood draw, no centrifugation and no processing time, and they avoid the variability of a patient's own platelet yield. PRP requires the draw and spin, and its potency depends on the individual patient. For throughput and standardisation, a manufactured product is simpler — though "consistent" only holds if the product itself is well characterised.

A Simple Framing

• Want an autologous, well-evidenced, injectable option → PRP
• Want an off-the-shelf topical adjunct to microneedling, accepting an emerging evidence base → exosomes
• Either way → the combination with microneedling is where much of the current interest sits

The two are not mutually exclusive; some clinics offer both and choose per patient and per goal. Supplies for plasma protocols sit in the PRP range.

The Takeaway

PRP is autologous, established and injectable; exosomes are manufactured, emerging and best kept topical. Neither is simply "better" — they occupy different points on the axes of evidence, regulation and convenience. For how exosomes pair with needling, see exosomes and microneedling.